JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A3012 Ruxolitinib (INCB018424)
4 Citation

Target: JAK

Summary: JAK inhibitor

insoluble in H2O; ≥15.32 mg/mL
A4112 Barasertib (AZD1152-HQPA)
3 Citation

Target: Aurora Kinases

Summary: Aurora Kinase B inhibitor, Potent and selective

≥25.4 mg/mL
A1905 3-Deazaneplanocin,DZNep
6 Citation

Target: Hydrolase

Summary: S-adenosylhomocysteine and EZH2 inhibitor

insoluble in EtOH; ≥17.07 mg/mL
B4894 SP2509

Target: Histone Demethylases

Summary: Demethylase 1 (LSD1) antagonist, novel Lysine-specific

insoluble in H2O; insoluble in EtOH; ≥19.45 mg/mL
A8182 3-Deazaneplanocin A (DZNep) hydrochloride
1 Citation

Target: EZH2

Summary: SAHH and EZH2 inhibitor

insoluble in EtOH; ≥14.94 mg/mL
A3692 OTX-015
3 Citation

Target: Bromodomains

Summary: BRD inhibitor

≥24.6 mg/mL
A3760 Reversine

Target: Aurora Kinases

Summary: A3 adenosine receptor antagonist,ARK-1/-2/-3 inhibitor

insoluble in H2O; ≥19.65 mg/mL
A3962 AZD1208

Target: Pim

Summary: PIM kinase inhibitor

insoluble in EtOH; insoluble in H2O; ≥18.95 mg/mL
A4490 I-CBP 112

Target: CREBBP|EP300

Summary: CBP/EP300 bromodomain inhibitor

≥49.6 mg/mL